Search
Temelimab
go.drugbank.com/drugs/DB15634InvestigationalTemelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
Empegfilgrastim
go.drugbank.com/drugs/DB16155InvestigationalEmpegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).
Casdatifan
go.drugbank.com/drugs/DB21701InvestigationalCasdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC) … Casdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Casdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor.
Ethyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Categories: Vitamin K AntagonistsGI heptapeptide
go.drugbank.com/drugs/DB15070InvestigationalGI heptapeptide is under investigation in clinical trial NCT01391208 (Esophageal Protocol for Detection of Neoplasia in the Digestive Tract).
Adelmidrol
go.drugbank.com/drugs/DB16083InvestigationalAdelmidrol is under investigation in clinical trial NCT01420510 (Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis).
Acacia
go.drugbank.com/drugs/DB10451ApprovedAcacia allergenic extract is used in allergenic testing.
Categories: Non-Standardized Plant Allergenic ExtractSynonyms: Plants and plant parts, gum, acacia or arabic acacia senegalBucillamine
go.drugbank.com/drugs/DB12160InvestigationalBucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.
Categories: Compounds used in a research, industrial, or household setting, Analgesics, Non-NarcoticCovax-19™
go.drugbank.com/drugs/DB15846InvestigationalPhase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).
Elebsiran
go.drugbank.com/drugs/DB19018InvestigationalElebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).